Your session is about to expire
← Back to Search
Dietary Supplement
Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients
N/A
Waitlist Available
Led By Kenneth Wilund, PhD
Research Sponsored by University of Illinois at Urbana-Champaign
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Summary
The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.
Eligible Conditions
- Dialysis Complication
- Chronic Kidney Disease
- Muscle Atrophy
- Kidney Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in lean mass over 6 months
Secondary study objectives
Change in physical function over 6 months
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: beta-hydroxy beta-methylbutyrateExperimental Treatment1 Intervention
Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
Group II: PlaceboPlacebo Group1 Intervention
The placebo group will consume non-nutritive placebo pills daily for 6 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HMB
2016
N/A
~200
Find a Location
Who is running the clinical trial?
University of Illinois at Urbana-ChampaignLead Sponsor
199 Previous Clinical Trials
40,424 Total Patients Enrolled
Kenneth Wilund, PhDPrincipal InvestigatorKinesiology & Community Health, UIUC
3 Previous Clinical Trials
54 Total Patients Enrolled